Published in Dis Model Mech on July 19, 2012
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem (1976) 903.81
Elevated C-reactive protein levels in overweight and obese adults. JAMA (1999) 9.94
The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol (2006) 9.61
Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw (2006) 7.19
Antiinflammatory properties of HDL. Circ Res (2004) 5.41
A peroxidase-coupled method for the colorimetric determination of serum triglycerides. Clin Chem (1983) 4.39
Quantitation of lipid phases in phospholipid vesicles by the generalized polarization of Laurdan fluorescence. Biophys J (1991) 3.47
Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest (1998) 3.34
Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest (1995) 3.14
Prader-Willi syndrome. Eur J Hum Genet (2008) 2.59
Biomarkers and potential mechanisms of obesity-induced oxidant stress in humans. Int J Obes (Lond) (2006) 2.36
Chronic inflammation in obesity and the metabolic syndrome. Mediators Inflamm (2010) 2.18
Population prevalence and estimated birth incidence and mortality rate for people with Prader-Willi syndrome in one UK Health Region. J Med Genet (2001) 1.94
Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation (2003) 1.78
Minireview: Inflammation and obesity pathogenesis: the hypothalamus heats up. Endocrinology (2010) 1.77
Impact of obesity on cardiovascular disease. Med Clin North Am (2011) 1.44
Oxidative stress and inflammation interactions in human obesity. J Physiol Biochem (2012) 1.43
Single vertical spin density gradient ultracentrifugation. Methods Enzymol (1986) 1.36
HDL: bridging past and present with a look at the future. FASEB J (2008) 1.29
Obesity and oxidative stress: a direct link to CVD? Arterioscler Thromb Vasc Biol (2003) 1.25
Ferrous ion oxidation in presence of xylenol orange for detection of lipid hydroperoxides in plasma. Methods Enzymol (1999) 1.22
The versatility of HDL: a crucial anti-inflammatory regulator. Eur J Clin Invest (2010) 1.21
Paraoxonase-1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. Biochem Biophys Res Commun (2004) 1.20
Structural modifications of HDL and functional consequences. Atherosclerosis (2005) 1.13
Anti-inflammatory properties of paraoxonase-1 in atherosclerosis. Adv Exp Med Biol (2010) 1.13
Validation of PON1 enzyme activity assays for longitudinal studies. Clin Chim Acta (2008) 1.12
Anti-oxidant properties of high-density lipoprotein and atherosclerosis. Clin Exp Pharmacol Physiol (2010) 1.11
The importance of high-density lipoproteins for paraoxonase-1 secretion, stability, and activity. Free Radic Biol Med (2004) 1.09
Antioxidant and cytoprotective properties of high-density lipoproteins in vascular cells. Free Radic Biol Med (2006) 1.09
Consumption of wonderful variety pomegranate juice and extract by diabetic patients increases paraoxonase 1 association with high-density lipoprotein and stimulates its catalytic activities. J Agric Food Chem (2008) 1.09
Leptin and the control of body weight: a review of its diverse central targets, signaling mechanisms, and role in the pathogenesis of obesity. Obesity (Silver Spring) (2009) 1.06
Antioxidant potential, paraoxonase 1, ceruloplasmin activity and C-reactive protein concentration in diabetic retinopathy. Clin Exp Med (2009) 1.05
Analytical and clinical performance of a detergent-based homogeneous LDL-cholesterol assay: a multicenter evaluation. Clin Chem (2000) 1.04
HDL-paraoxonase and membrane lipid peroxidation: a comparison between healthy and obese subjects. Obesity (Silver Spring) (2009) 1.02
Paraoxonase activity in high-density lipoproteins: a comparison between healthy and obese females. J Clin Endocrinol Metab (2004) 1.01
Paraoxonase: a multifaceted biomolecule. Clin Chim Acta (2009) 0.97
The metabolic phenotype of Prader-Willi syndrome (PWS) in childhood: heightened insulin sensitivity relative to body mass index. J Clin Endocrinol Metab (2010) 0.93
Characteristics of cardiac and vascular structure and function in Prader-Willi syndrome. Clin Endocrinol (Oxf) (2007) 0.90
Mortality in Prader-Willi syndrome. Am J Ment Retard (2006) 0.90
Relationship of endogenous hyperleptinemia to serum paraoxonase 1, cholesteryl ester transfer protein, and lecithin cholesterol acyltransferase in obese individuals. Metabolism (2007) 0.88
The Italian National Survey for Prader-Willi syndrome: an epidemiologic study. Am J Med Genet A (2008) 0.88
High-density lipoprotein: a potent inhibitor of inflammation. Clin Exp Pharmacol Physiol (2009) 0.87
Pathophysiological implications between chronic inflammation and the development of diabetes and obesity. Cir Cir (2011) 0.87
Human paraoxonase-1 gene expression by HepG2 cells is downregulated by interleukin-1beta and tumor necrosis factor-alpha, but is upregulated by interleukin-6. Life Sci (2003) 0.87
Dysfunctional high-density lipoprotein and atherosclerosis. Curr Atheroscler Rep (2010) 0.87
Gender related differences in paraoxonase 1 response to high-fat diet-induced oxidative stress. Obesity (Silver Spring) (2008) 0.86
High C-reactive protein and low paraoxonase1 in diabetes as risk factors for coronary heart disease. Atherosclerosis (2005) 0.85
Free and total leptin serum levels and soluble leptin receptors levels in two models of genetic obesity: the Prader-Willi and the Down syndromes. Metabolism (2007) 0.84
Prader-Willi syndrome is associated with activation of the innate immune system independently of central adiposity and insulin resistance. J Clin Endocrinol Metab (2010) 0.83
Development and validation of an automated and ultrasensitive immunoturbidimetric assay for C-reactive protein. Clin Chem (2000) 0.82
Human paraoxonase-1 activity in childhood obesity and its relation to leptin and adiponectin levels. Pediatr Res (2010) 0.81
GH replacement reduces increased lipid peroxidation in GH-deficient adults. Clin Endocrinol (Oxf) (2007) 0.81
Paraoxonase 1 arylesterase activity and mass are reduced and inversely related to C-reactive protein in patients on either standard or home nocturnal hemodialysis. Clin Nephrol (2010) 0.80
Adult subjects with Prader-Willi syndrome show more low-grade systemic inflammation than matched obese subjects. J Endocrinol Invest (2008) 0.80
Immunonephelometric assay of human apolipoprotein AI. Clin Chem (1980) 0.80
Inflammatory markers in adults with Prader-Willi syndrome before and during 12 months growth hormone treatment. Horm Res (2006) 0.79
Body fat excess and stimulated growth hormone levels in adult patients with Prader-Willi syndrome. Am J Med Genet A (2009) 0.78
Effect of homocysteinylation on high density lipoprotein physico-chemical properties. Chem Phys Lipids (2009) 0.78
Fluorescence analysis of lipoprotein peroxidation. Methods Enzymol (1994) 0.78
Serum paraoxonase activity, high-sensitivity C-reactive protein, and lipoprotein disturbances in end-stage renal disease patients on long-term hemodialysis. J Clin Lipidol (2008) 0.78
Relation of plasma leptin to lipoproteins in overweight children undergoing weight reduction. Int J Obes Relat Metab Disord (1999) 0.77
The role of growth hormone and insulin-like growth factor I in oxidative processes. Endokrynol Pol (2009) 0.76
Analysis of endothelial protein C receptor gene and metabolic profile in Prader-Willi syndrome and obese subjects. Obesity (Silver Spring) (2011) 0.76
C-reactive protein levels in subjects with Prader-Willi syndrome and obesity. Genet Med (2006) 0.76
Effect of genistein against copper-induced lipid peroxidation of human high density lipoproteins (HDL). Atherosclerosis (2004) 0.76
Comparison between beta-cell function and insulin resistance indexes in prepubertal and pubertal obese children. Metabolism (2002) 1.14
The gluten-free diet: safety and nutritional quality. Nutrients (2010) 1.13
Structural modifications of HDL and functional consequences. Atherosclerosis (2005) 1.13
Antioxidant and cytoprotective properties of high-density lipoproteins in vascular cells. Free Radic Biol Med (2006) 1.09
HDL-paraoxonase and membrane lipid peroxidation: a comparison between healthy and obese subjects. Obesity (Silver Spring) (2009) 1.02
Reactive oxygen species plasmatic levels in ischemic stroke. Mol Cell Biochem (2007) 0.99
Strength characterization of knee flexor and extensor muscles in Prader-Willi and obese patients. BMC Musculoskelet Disord (2009) 0.99
Clinical implications of gait analysis in the rehabilitation of adult patients with "Prader-Willi" Syndrome: a cross-sectional comparative study ("Prader-Willi" Syndrome vs matched obese patients and healthy subjects). J Neuroeng Rehabil (2007) 0.98
Celiac disease, inflammation and oxidative damage: a nutrigenetic approach. Nutrients (2012) 0.92
On the origin of sensory impairment and altered pain perception in Prader-Willi syndrome: a neurophysiological study. Eur J Pain (2008) 0.91
Cherry antioxidants: from farm to table. Molecules (2010) 0.91
Lipid peroxidation in stroke patients. Clin Chem Lab Med (2008) 0.90
Effect of homocysteinylation of low density lipoproteins on lipid peroxidation of human endothelial cells. J Cell Biochem (2004) 0.86
Lipid peroxidation in hemodialysis patients: effect of vitamin C supplementation. Clin Biochem (2007) 0.86
Assessment of central adrenal insufficiency in children and adolescents with Prader-Willi syndrome. Clin Endocrinol (Oxf) (2012) 0.85
Effectiveness of a 6-month home-based training program in Prader-Willi patients. Res Dev Disabil (2010) 0.85
Genetics and mathematics: evidence from Prader-Willi syndrome. Neuropsychologia (2007) 0.84
Gait patterns in Prader-Willi and Down syndrome patients. J Neuroeng Rehabil (2010) 0.84
The effects of muscle hypotonia and weakness on balance: a study on Prader-Willi and Ehlers-Danlos syndrome patients. Res Dev Disabil (2011) 0.84
Olive oil supplemented with menaquinone-7 significantly affects osteocalcin carboxylation. Br J Nutr (2011) 0.83
Fractal dimension approach in postural control of subjects with Prader-Willi Syndrome. J Neuroeng Rehabil (2011) 0.82
Characterisation of balance capacity in Prader-Willi patients. Res Dev Disabil (2010) 0.80
Increased plasma concentrations of palmitoylethanolamide, an endogenous fatty acid amide, affect oxidative damage of human low-density lipoproteins: an in vitro study. Atherosclerosis (2005) 0.80
Peroxidation of lipoproteins in multiple sclerosis. J Neurol Sci (2011) 0.80
Postural adaptations to long-term training in Prader-Willi patients. J Neuroeng Rehabil (2011) 0.80
The effect of vision on postural strategies in Prader-Willi patients. Res Dev Disabil (2011) 0.80
The impact of growth hormone/insulin-like growth factor-I axis and nocturnal breathing disorders on cardiovascular features of adult patients with Prader-Willi syndrome. J Clin Endocrinol Metab (2005) 0.80
Quality of life assessment in a sample of patients affected by Prader-Willi syndrome. J Paediatr Child Health (2007) 0.79
Growth hormone response to standard provocative stimuli and combined tests in very young children with Prader-Willi syndrome. Horm Res Paediatr (2014) 0.79
Postural strategies in Prader-Willi and Down syndrome patients. Res Dev Disabil (2010) 0.79
Gait pattern in two rare genetic conditions characterized by muscular hypotonia: Ehlers-Danlos and Prader-Willi syndrome. Res Dev Disabil (2011) 0.78
Conditional cardiovascular response to growth hormone therapy in adult patients with Prader-Willi syndrome. J Clin Endocrinol Metab (2007) 0.78
Effect of homocysteinylation on high density lipoprotein physico-chemical properties. Chem Phys Lipids (2009) 0.78
Skeletal muscle characteristics and motor performance after 2-year growth hormone treatment in adults with prader-willi syndrome. J Clin Endocrinol Metab (2014) 0.78
Sleep cycling alternating pattern (CAP) expression is associated with hypersomnia and GH secretory pattern in Prader-Willi syndrome. Sleep Med (2006) 0.78
Exploring patterns of unwanted behaviours in adults with Prader-Willi syndrome. J Appl Res Intellect Disabil (2013) 0.77
Long-term echocardiographic and cardioscintigraphic effects of growth hormone treatment in adults with Prader-Willi syndrome. J Clin Endocrinol Metab (2015) 0.77
Adults with Prader-Willi syndrome have weaker bones: effect of treatment with GH and sex steroids. Calcif Tissue Int (2015) 0.77
Effect of obesity onset on pendular energy transduction at spontaneous walking speed: Prader-Willi versus nonsyndromal obese individuals. Obesity (Silver Spring) (2013) 0.77
The fractal dimension approach in posture: a comparison between Down and Prader-Willi syndrome patients. Comput Methods Biomech Biomed Engin (2013) 0.77
Growth hormone therapy and respiratory disorders: long-term follow-up in PWS children. J Clin Endocrinol Metab (2013) 0.77
Olive oil supplemented with Coenzyme Q(10): effect on plasma and lipoprotein oxidative status. Biofactors (2012) 0.76
Analysis of endothelial protein C receptor gene and metabolic profile in Prader-Willi syndrome and obese subjects. Obesity (Silver Spring) (2011) 0.76
Effect of phytosterols on copper lipid peroxidation of human low-density lipoproteins. Nutrition (2009) 0.76
Growth hormone in health and disease: Prader-Willi syndrome--GH therapy and bone. Nat Rev Endocrinol (2013) 0.76
Copper-induced oxidative damage on astrocytes: protective effect exerted by human high density lipoproteins. Biochim Biophys Acta (2003) 0.76
Protective effect of human HDL against Cu(2+)-induced oxidation of astrocytes. J Trace Elem Med Biol (2003) 0.75
Corticospinal physiology in patients with Prader-Willi syndrome: a transcranial magnetic stimulation study. Arch Neurol (2004) 0.75
Lipid peroxidation and paraoxonase-1 activity in celiac disease. J Lipids (2012) 0.75
Higher Levels of Oxidized Low Density Lipoproteins in Alzheimer's Disease Patients: Roles for Platelet Activating Factor Acetyl Hydrolase and Paraoxonase-1. J Alzheimers Dis (2015) 0.75
Is non-alcoholic fatty liver disease less frequent among women with Prader-Willi syndrome? Obes Facts (2014) 0.75
Influence of age, gender, and glucose tolerance on fasting and fed acylated ghrelin in Prader Willi syndrome. Clin Nutr (2009) 0.75
Use of GLP-1 receptor agonists in Prader-Willi Syndrome: report of six cases. Diabetes Care (2014) 0.75
Effect of acylethanolamides on lipid peroxidation and paraoxonase activity. Biofactors (2008) 0.75
Potential involvement of nicotinamide N-methyltransferase in the pathogenesis of metabolic syndrome. Metab Syndr Relat Disord (2015) 0.75